Fireside Chat, Panel, Interview
The Role of Universities in Accelerating Bioscience Research
Milken InstituteDavid Baltimore, Joel Burdick, James Economou, Michael Quick, Owen Witte, Stephen Mayo, Steve Mayo, Nick, Francis Collins, Remy, Joe Boistak, Charles, Eric Green, Ray Deshaies
- Future biological research is expected to translate into applications in healthcare, with a specific focus on engineering biological materials and using viruses as gene carriers to prevent HIV transmission, though current testing remains at the animal model stage before human trials.
- Institutions like Caltech and USC plan to integrate biology with engineering through new divisions and programs, aiming to produce researchers proficient in both fields and to accelerate the translation of therapeutic concepts from basic research to clinical trials within less than seven years.
- Academic and clinical translation models are evolving to allow institutions to prove therapeutic value internally rather than relying solely on pharmaceutical hand-offs, supported by specialized grant mechanisms, foundation support, and the establishment of national consortia requiring interaction between clinical translational institutes.
- Large medical device and pharma companies are increasingly reluctant to provide early-stage risk capital for high-cost technologies like spinal cord stimulation, creating a dependency on academic entrepreneurs, NIH grants, and foundation support to bridge the "valley of death."
- The venture capital landscape faces a funding bottleneck due to the lack of episodic angel funding and institutional investor hesitation regarding small investment amounts between $50,000 and $500,000, prompting calls for new structures such as themed asset pools, mutual funds, or corporate venturing initiatives.
- New conflict of interest guidelines are projected to primarily increase compliance costs without significantly hindering industry partnerships, while a shift in U.S. patent law to "first to file" is noted to have caused industry tension but no apparent impact at Caltech.
- Strategic partnerships between universities and pharmaceutical firms will continue to be essential for accessing human disease biology insights and biomarkers, supported by coordinated ecosystems that include proof-of-concept grants and adjusted academic reward systems to recognize team science and entrepreneurship.
- Significant risks include the potential for aggregation of funds to result in insufficient capital for individual projects, the legal uncertainties surrounding academic-industry patents following the Stanford v. Roche decision, and the general requirement for continuous large-scale capital access to fully manifest academic-industry evolution plans.